Trials / Unknown
UnknownNCT02510469
Apatinib as Maintenance Therapy After Adjuvant Chemotherapy in Progressive Gastric Cancer With Positive Exfoliative Cancer Cells
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- Hebei Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy and safety of apatinib as maintenance therapy after adjuvant chemotherapy in progressive gastric cancer patients with positive exfoliative cancer cells.
Detailed description
Eligible patients will recieve apatinib treatment(500mg qd p.o. q28d) for 6 cycles after 8 cycles of XELOX adjuvant chemotherapy or only XELOX adjuvant chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apatinib | Apatinib Mesylate Tablets 500 mg qd p.o. |
Timeline
- Start date
- 2015-07-01
- Primary completion
- 2018-07-01
- Completion
- 2018-07-01
- First posted
- 2015-07-29
- Last updated
- 2017-10-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02510469. Inclusion in this directory is not an endorsement.